Results 211 to 220 of about 87,574 (284)

Patient-centered outcomes with subcutaneous immunoglobulin use for infection control in primary and secondary immunodeficiencies: data of a GEIE Spanish Registry. [PDF]

Front Immunol
Martínez Mercader S, Garcia-Bustos V, Moral Moral P, Martínez Buenaventura C, Escudero Vergara E, Montaner Bosch MC, Balastegui-Martín H, Galindo Maycas S, Palací Mur B, Escobar Palazón M, Moreno Mulet M, Campanero Carrasco I, López A, Hernández Ruiz CD, Ruiz-López L, Guzmán Guzmán R, Cabañero-Navalon MD.   +16 more
europepmc   +1 more source

Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases. [PDF]

J Clin Immunol
Patel NC, Walter JE, Wasserman RL, Rubinstein A, Kankirawatana S, Shepherd MW, Greco E, Li Z, Russo-Schwarzbaum S, Saeed-Khawaja S, McCoy B, Yel L.   +11 more
europepmc   +1 more source

Guideline for the In Vivo Immunomodulatory Activity Test of Polysaccharide Based on Cyclophosphamide‐Induced Mouse Model

Food Safety and Health, EarlyView.
Abstract graph of the in vivo immunomodulatory activity of polysaccharide based on a cyclophosphamide‐induced mouse model. ABSTRACT The immune system serves as the primary defense mechanism against pathogens and plays a vital role in maintaining host homeostasis. In recent years, natural polysaccharides have emerged as promising immunomodulators due to
Wenlei Nie, Xuecong Tong, Qiao Ding, Xiaojun Huang   +3 more
wiley   +1 more source

Current Practice and Perspectives on Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Antibody Deficiency Among Specialized Nurses in Poland. [PDF]

Nurs Rep
Mizera D, Dziedzic R, Drynda A, Matyja-Bednarczyk A, Padjas A, Celińska-Löwenhoff M, Jakieła B, Bazan-Socha S.   +7 more
europepmc   +1 more source

Construction of a clickable probe‐based protein chip platform for discovering covalent mIDH1 inhibitors from natural medicinal extracts

iMeta, EarlyView.
In this study, we develop a flexible Ccc‐Chip (protein microarray + bioorthogonal click chemistry) for high‐throughput screening of natural covalent active molecules from medicinal plant extracts, identifying flavokawain C from Piper methysticum Forst as a novel covalent mIDH1 inhibitor.
Zhao Cui, Jiameng Li, Caifeng Li, Mo Sun, Wei Liu, Xuxia Cao, Shiwen Deng, Junxian Cao, Hongjun Yang, Peng Chen   +9 more
wiley   +1 more source

Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort. [PDF]

J Clin Immunol
Yalcin Gungoren E, Yorgun Altunbas M, Dikici U, Meric Z, Eser Simsek I, Kiykim A, Can S, Karabiber E, Yakici N, Orhan F, Cokugras H, Aydogan M, Ozdemir O, Bilgic Eltan S, Baris S, Ozen A, Karakoc-Aydiner E.   +16 more
europepmc   +1 more source

Ophidiomycosis Prevalence and Disease Ecology in a Natrix tessellata (Laurenti, 1768) Population From Northern Italy

Journal of Experimental Zoology Part A: Ecological and Integrative Physiology, EarlyView.
ABSTRACT Fungal pathogens pose a growing threat to vertebrate biodiversity. In snakes, Ophidiomyces ophidiicola (Oo) has garnered particular concern, although its impact in Europe remains poorly understood. We conducted a season‐long, standardized survey of dice snakes (Natrix tessellata) along the northern shore of Lake Como (Italy) to quantify Oo and
Matteo Riccardo Di Nicola, Luca Colla, Kevin P Mulder, Federico Storniolo, Elin Verbrugghe, Giuseppe Esposito, Donato A. Grasso, Frank Pasmans, An Martel   +8 more
wiley   +1 more source

Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study. [PDF]

Immunotherapy
Ellerbroek PM, Hanitsch LG, Witte T, Lougaris V, Hagen PMV, Paassen PV, Chen J, Fielhauer K, McCoy B, Nagy A, Yel L.   +10 more
europepmc   +1 more source

Severe allergic reaction to ustekinumab reinitiation in a pediatric patient with Crohn's disease: A case report

JPGN Reports, EarlyView.
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling, Shauna Schroeder, Brad Pasternak   +2 more
wiley   +1 more source

Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial. [PDF]

J Peripher Nerv Syst
Hadden RDM, Andersen H, Bril V, Basta I, Rejdak K, Duff K, Greco E, Hasan S, Anderson-Smits C, Ay H.   +9 more
europepmc   +1 more source